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Abstract
Hormone levels shift the immune state in HIV-uninfected pregnant and breastfeeding women away from Th1 responses and
toward regulation to permit fetal tolerance. Limited data exist on inflammation during pregnancy or postpartum in HIV-
infected women, though certain inflammatory markers are associated with adverse health outcomes among HIV-infected
persons. We measured hsCRP, D-dimer, IFN-c, IL-6, IL-10 and TNF-a at 34 weeks gestation and six months postpartum in
HIV-infected women from the Botswana Mashi PMTCT trial who were randomized to breastfeeding or formula-feeding.
Differences in inflammatory markers between gestation and postpartum periods, and by randomized feeding method, were
estimated using generalized estimating equations, adjusting for baseline plasma HIV-1 viral load, CD4 count, calendar time,
and antiretroviral treatment status. Additionally, we studied the association between marker concentrations at six months
postpartum and major adverse clinical events over the following 4.5 years, using case-cohort sampling and adjusted Cox
proportional hazards models. In 86 breastfeeding and 75 formula-feeding women, hsCRP and D-dimer decreased
significantly between 34 weeks gestation and six months postpartum, while IFN-c increased. There was no significant
association between inflammatory marker change and randomized feeding method after adjusting for multiple
comparisons and removing outliers. In univariate analysis, TNF-a, D-dimer, and IFN-c concentrations at six months
postpartum were significant predictors of subsequent clinical events, and TNF-a remained significant in multivariate analysis
(HR= 4.16, p = 0.001). In young HIV-infected women in Botswana inflammatory marker concentrations did not differ
significantly between women who breast- vs. formula-fed. However, postpartum TNF-a level was predictive of subsequent
adverse clinical event.
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Introduction
Pregnancy and breastfeeding are associated with modulation of
the immune system toward immune regulation and reduced Th1
responses [1,2]. Hormonal changes during pregnancy, which
persist in part during breastfeeding, are one cause of this immune
shift [3]; breastfeeding and the hormone prolactin have been
shown to be associated with B-cell production and reduced
inflammatory responses [4,5]. Such data support a hypothesis that
breastfeeding could, at least transiently, influence HIV-1 disease
progression through regulation of the immune response. Some,
but not all [6,7,8], studies suggest that breastfeeding is associated
with more rapid CD4 count decline or adverse health outcomes
among HIV-infected women [9]. In one trial conducted in Kenya
among HIV-infected women without access to antiretroviral
treatment (ART), women randomized to breastfeeding had a
higher mortality at two-years postpartum compared with those
randomized to formula-feeding (10.5% vs. 3.8%, respectively)
[10]. Similarly, a trend toward more rapid progression to AIDS or
death was observed at six months postpartum in women
randomized to breastfeeding in the Botswana Mashi trial, possibly
as a result of higher maternal inflammation as suggested by CRP
level, despite similar micronutrient level [11]. The cause of this
potentially higher rate of HIV disease progression and adverse
clinical outcomes associated with breastfeeding among HIV-
infected women is unknown, and to our knowledge there are no
published data on the association between inflammation and
breastfeeding in HIV-infected women.
Levels of certain inflammatory markers, such as C-reactive
protein, IL-6, and D-dimer, have been independently associated
with subsequent morbidity and mortality in HIV-1-infected
individuals in some [12,13,14,15,16,17,18] but not all [19] studies.
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However, many of these study populations were predominantly
comprised of older men, and few studies included data from
women of childbearing age or postpartum women [13]. The
potential for a predictive role of inflammatory markers in HIV
disease progression has not been explored in HIV-infected women
from resource-limited settings, where other co-morbidities (includ-
ing co-infections) may render these markers less informative.
Using stored samples from participants in a previously-
completed randomized trial in Botswana that included feeding
and antiretroviral interventions to prevent mother-to-child HIV
transmission (the Mashi study) [20], we investigated two distinct
aims: 1) the relationship between markers of inflammation
between the third trimester and six months postpartum overall
and by randomized feeding strategy (breastfeeding vs. formula-
feeding); and 2) whether concentrations of inflammatory markers
in otherwise healthy HIV-infected women at six months postpar-
tum correlated with morbidity and mortality over a subsequent
4.5-year follow-up period.
Methods
Participants
The study was approved by the IRBs of both the Harvard
School of Public Health and the Botswana Ministry of Health.
Women provided written informed consent for study participation
and storage/use of samples/data. We used stored samples and
data from the completed Mashi mother-to-child HIV transmission
(MTCT) prevention trial in Botswana (ClinicalTrials.gov registra-
tion number NCT00197587). The Mashi trial randomized 1200
HIV-infected women to six months of breastfeeding plus six
months of infant zidovudine prophylaxis, or to formula-feeding
plus infant zidovudine for one month, as previously described [20].
Women in the breastfeeding arm were asked to exclusively
Figure 1. Selection of subcohorts. For Aim 1, we selected at random 86 women from the breastfeeding and 75 women from the formula-feeding
arms of the Mashi Study. For Aim 2, a case was defined as a woman who had a six-month postpartum sample available, and experienced a major
adverse clinical event after, but not before, eight months postpartum. Women randomly selected for Aim 1 who did not experience any adverse
clinical events comprised the controls for Aim 2.
doi:10.1371/journal.pone.0089928.g001
Table 1. Case diagnoses.
Grade 3/4 AIDS-Defining Death
Peripheral Neuropathy (n = 2)a Persistent HPV- LGSIL TB-related diagnosis (n = 20)e Eclampsia
Abscess CIN 3 Esophageal Candidiasis Renal Failure
Neutropenia Cervical Carcinoma in situ Cervical Cancer Hepatic Encephalopathy
Dysfunctional Uterine Bleeding Cellulitis (n = 2) Squamous Cell Carcinoma Anemia
Generalized Blistering Rash Cervicitis (n = 3)d Chronic Gastroenteritis
Acute Otitis Mediab Meningitis
Herpes Zoster (n = 2) Bacterial Meningitis
Anal Fissure Unknown
Kaposi Sarcomac
aOne participant additional diagnosis of gangrene, the other rectal divercation one month later.
bPrevious diagnosis with ovarian cyst.
cThree months later sepsis.
dOne simultaneously diagnosed with gastroenteritis, another later diagnosed with cryptococcal meningitis.
eTwo participants with TB-related diagnoses had multiple diagnoses at the same visit (lymphadenitis, pleural effusion); one participant had an additional diagnosis of
cervicitis 15 months later and meningococcal meningitis 32 months later.
doi:10.1371/journal.pone.0089928.t001
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breastfeed for five months then initiate weaning in order to fully
wean to formula by six months postpartum. Women were enrolled
between 33 and 35 weeks’ gestation during 2001 to 2003, and
were followed for up to five years postpartum. HIV RNA plasma
viral load and CD4 cell count were tested at enrollment (,34
weeks gestation), delivery, and then approximately every six
months postpartum for at least two years (plasma was stored at
these time points). All women received zidovudine from enroll-
ment through delivery; in 2002 (19 months into enrollment), three-
drug ART became available and was offered to all HIV-infected
infants and to all women with a CD4 count ,200 cells/ml or
history of an AIDS-defining illness. Women provided written
informed consent for study participation and storage/use of
samples/data.
Study design
The first part of this study was to characterize changes in
inflammatory markers over time in each feeding arm - from 34
weeks gestation to six months postpartum - and to compare levels
of inflammatory markers between randomized feeding arms at
both time points. The estimated sample size needed to provide
80% power to detect a difference of one standard deviation in
most marker levels at alpha= .05 was 67 per randomized feeding
arm. From the Mashi cohort we selected a random sample of 86
women in the breastfeeding arm and 75 women in the formula
feeding arm among those with plasma samples available at both
enrollment and six months postpartum (PP) (Fig. 1).
The second part of this study was to analyze whether
inflammatory marker concentration at six months postpartum
predicted subsequent major adverse clinical outcomes, using a
case-cohort study design [21]. An adverse clinical event was
defined as death, an AIDS-defining illness, or a diagnosis of grade
3 or 4 (severe or life-threatening) illness (Table 1). Grade 3 or 4
conditions that were assumed to have no relationship to
inflammation and/or HIV disease were excluded (e.g. repeat
pregnancy, injury, migraine headache). A case was defined as a
woman who had a six-month postpartum sample available for
testing and experienced a major adverse clinical event after eight
months postpartum but no previous major adverse clinical event
documented by the study team prior to this time. Women in the
cohort were those selected for the first study aim who also did not
experience any adverse clinical events prior to eight-months
postpartum in order to reduce the likelihood that biomarker
concentrations at six months were influenced by concurrent illness
(n = 149, Fig. 1; five formula-feeding and seven breastfeeding
women who experienced illness prior to eight months were
excluded from this case-cohort sample). With 10% of participants
experiencing a qualifying adverse clinical outcome in the total
cohort, a subcohort size of 12% (n= 144) would have 80% power
to detect a hazard ratio (HR) of 1.4 [22].
Laboratory Analysis
Blood plasma samples were tested for interleukin-6 (IL-6),
tumor necrosis factor alpha (TNF-a), and interleukin-10 (IL-10) by
ultrasensitive ELISA (Invitrogen Life Sciences, Carlsbad, CA);
interferon-gamma (IFN-c) by standard ELISA (Invitrogen Life
Sciences, Carlsbad, CA); D-dimer by Cobas Integra 400 System
(Tina-quant D-Dimer Gen.2); and high sensitivity C-reactive
protein (hsCRP) by protein-latex assay (Roche, Basel, Switzer-
land). All ELISA and Cobas reagents were from the same lot for
all tests. Samples were not divided by analysis subgroup during
testing to reduce potential confounding due to variability between
assay runs.
Statistical Analysis
Statistical calculations were performed using STATA (version
8.2 for Macintosh, College Station, TX), and SAS (version 9.3,
Cary, NC). For Aim 1 we used generalized estimating equations
(GEE) to compare inflammatory marker concentrations over time
and whether feeding arm was significantly associated with changes
over time, using a binomial link for dichotomous and an identity
link for continuous markers (each marker in a separate equation).
To account for differences between feeding arms at enrollment,
and previously published associations between plasma viral load/
CD4 T cell count and inflammation, all models were adjusted for
CD4 T cell count, HIV-1 plasma viral load, calendar time, and for
ART initiation between enrollment and six months postpartum.
As a high proportion of samples had concentrations below the
level of detection (62% for IFN-c, 69% for IL-10, and 41% for
TNF-a), these were modeled as detected/undetected dichotomous
observations. Breastfeeding and undetected inflammatory marker,
where applicable, were the referents in all models. Although
Table 2. Patient characteristics at 34 weeks gestation and six months post-partum.
Breastfeeding Formula Feeding
n
34 Weeks
Gestation
6 months
post-partum p valuec n
34 Weeks
Gestation
6 months
post-partum p valuec
Viral load (log10 RNA copies/
ml)a
83 4.25 (4.1, 4.4) 4.20 (4.0, 4.4) .79 71 4.1 (3.9, 4.3) 4.0 (3.8, 4.2) .71
CD4 count (cells/ml)a 81 448 (393, 503) 440 (386, 494) .84 67 398 (354, 442) 472 (416, 527) .01
CRP (mg/mL)a 78 4.24 (1.8, 9.8) 3.02 (1.1, 4.8) .009 68 3.21 (1.8, 5.5) 1.50 (0.59, 4.0) .002
IL-6 (pg/mL)a 84 0.50 (0.28, 0.91) 0.54 (0.12, 1.2) .58 75 0.41 (0.17, 0.99) 0.87 (0.48, 1.6) ,.001
D-dimer (pg/mL)a 73 1.4 (0.94, 2.4) 0.40 (0.29, 0.57) ,.001 66 1.32 (0.93, 1.8) 0.52 (0.31, 0.67) ,.001
TNF-a (%)b 81 68 (57, 78) 53 (42, 64) .11 73 41 (29, 53) 55 (43, 66) .03
IFN-c (%)b 84 21 (13, 31) 46 (35, 58) ,.001 74 33 (23, 45) 62 (50, 73) ,.001
IL-10 (%)b 70 27 (18, 37) 24 (15, 36) 1.0 71 25 (16, 37) 37 (25, 49) .09
aMedian value (interquartile range).
bMedian % of samples with detected concentration of marker (95% CI).
cP-values obtained from Wilcoxon signed-rank test between timepoints.
doi:10.1371/journal.pone.0089928.t002
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feeding strategy was randomized, mean enrollment values of
hsCRP and TNF-a were significantly different at baseline between
the strata. Sensitivity analyses including these variables were
performed for all models. The main model outcomes were time
(34 weeks gestation or six months postpartum), group (feeding
strategy arm), and group*time (interaction) covariates. For IL-6, a
small group of influential observations (n = 11, Pearson residuals
,24) had values near the lower limit of detection of the assay, and
removing these outliers influenced the statistical significance of the
time covariate (from a p-value of .037 to .23) and group*time
interaction (from a p-value of ,.001 to .08). When compared to
the rest of the subcohort, the outliers had no unique character-
istics: no common test date, assay batch, or clinical characteristics
of the participants. The significant influence of this small number
of observations led us to remove them from our analyses, but kept
them in the calculation of means for completeness in our
reporting.
Aim 2 (association of inflammatory markers with subsequent
morbidity/mortality) was investigated using Cox Proportional
Hazards models with appropriate weighting for our case-cohort
design [23]. Univariate and multivariate models were fit for each
proinflammatory marker. The adjusted models included the
following covariates: maternal age at enrollment, six month
postpartum HIV RNA viral load, six month postpartum CD4 T
cell count, randomized feeding arm, and delivery calendar time
represented by 12 three-month periods (calendar time of delivery
adjusts for potential changes in public health practice).
Results
Participant Characteristics
We selected at random 86 women from the breastfeeding and
75 women from the formula-feeding arms of the Mashi Study.
Women in this subcohort had slightly a higher median CD4 count
(393 vs. 355 cells/ml, respectively, p = .04) and lower median HIV-
1 RNA (4.2 vs. 4.4 log10 RNA copies/ml respectively, p= .05) at
enrollment at 34 weeks gestation, compared with all women
participating in the Mashi trial, but were similar in age and sites of
enrollment (data not shown). Between breastfeeding and formula-
feeding arms within the subcohort, there was no difference at
enrollment in median CD4 count (p = .18), or in median viral load
(p = .13) (median concentrations in Table 2, p-values between
arms not shown). Similar clinical characteristics were seen in both
arms at six months postpartum (Table 2).
Between the formula and breastfeeding arms at enrollment,
differences were found in the concentrations of TNF-a, 68% vs.
41% with detected concentrations in the formula and breastfeed-
ing arms, respectively (p = .01), and hsCRP (4.24 vs. 3.21 ng/ml,
p = .001). Only hsCRP was significant after adjusting for multiple
comparisons (significant p,0.008). Sensitivity analyses including
TNF-a and hsCRP as covariates did not alter the interpretation of
the results described below. There were no differences in D-dimer,
IFN-c, IL-6 and IL-10 plasma concentration at enrollment
between the two arms (data not shown).
TNF-a was significantly correlated with viral load at enrolment
(r = .422, p,.001) (Fig. 2A) and six months postpartum (r = .412,
p,.001) (Fig. 2B) as was CD4 count at both time points
(r =2.170, p = .036 and r =2.231, p = .006, respectively); no
other marker concentrations were associated with either viral load
or CD4 T cell count.
Markers of inflammation vary over time but not by infant
feeding strategy
Changes in inflammatory marker concentrations from 34 weeks
gestation to six months postpartum were similar in the breastfeed-
ing and formula-feeding women after accounting for multiple
comparisons (time*group interaction term p..008 for all),
demonstrating no effect of randomized infant feeding strategy on
changes in biomarkers over time (Figure 3).
Concentrations of three out of the six markers of inflammation
and coagulation tested were significantly different between 34
weeks gestation and six months postpartum overall: decreases were
seen over time for hsCRP in the breastfeeding (4.24 vs. 3.02 ng/
ml, nearly significant p = .009) and formula-feeding arms (3.21 vs.
1.50 ng/ml (p = .002) and also for D-dimer in the breastfeeding
(1.40 vs. 0.40 ng/ml (p,.001) and formula-feeding arms (1.32 vs.
0.52 ng/ml, p,.001) (Table 2). IFN-c increased in the breastfeed-
ing (21 vs. 46 with detected concentrations (p,.001) and formula-
feeding arms (33 vs. 62 with detected concentrations (p,.001,
Table 2). Concentrations of the other three biomarkers, IL-6, IL-
10, and TNF-a, after removing outliers and controlling for
multiple comparisons, did not significantly change between the
gestation and postpartum periods.
TNF-a and IFN-c concentrations at six months
postpartum are associated with subsequent adverse
clinical outcomes
In univariate models the hazard of experiencing an adverse
clinical event increased significantly with a 1 pg/ml higher
concentration of D-dimer (p= .007) and with detection of TNF-
a at six months (p,.001) (Table 3). The hazard of a subsequent
clinical event decreased with detection of IFN-c at six months
postpartum (p= .009) (Table 3). There was no significant
association between the concentration of hsCRP, IL-10 or IL-6
and a subsequent clinical event in univariate analyses. For
multivariate models, covariates known to be associated with both
biomarker concentrations and clinical outcome were included:
maternal enrollment plasma HIV-1 RNA load and CD4 T cell
count, randomized feeding strategy, age, calendar time, and ART
initiation during follow-up. Results of the multivariate model were
similar, although higher D-dimer (p = .07) and lower IFN-c
(p = .01) were no longer statistically significantly associated with
clinical outcome (with a significant p-value of 0.008 after
considering multiple comparisons). TNF-a remained associated
with adverse clinical events after considering multiple comparisons
(p = .001) (Table 3). The multivariate model was a better fit than
the univariate for all markers (by likelihood ratio test).
Discussion
Previously published studies have reported increased mortality
or HIV disease progression among HIV-infected women random-
ized to breastfeeding [10,13], with unknown underlying mecha-
nisms to explain these findings. We present the first data
examining the relationship of multiple inflammatory and coagu-
lation biomarkers with excess mortality/AIDS associated with
breastfeeding. We did not find a robust association between
inflammatory and coagulation biomarkers and breastfeeding,
which suggests that either the power in this study was not
sufficient to detect an association, the availability of ART in this
Figure 2. Association of viral load and CD4 count with cytokine expression. Viral load (red) is shown on the left y axis, and CD4 count (blue)
on the right y axis. (a) association with cytokine expression at enrollment; (b) association with cytokine expression at six months postpartum.
doi:10.1371/journal.pone.0089928.g002
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study may have influenced the results, or inflammation as
measured by these six biomarkers may not explain these previous
findings.
There are few published data describing inflammatory bio-
markers in peripartum HIV-infected women, and those available
are from US-based cohorts and each report on few markers and
different timing of sample collection, providing little generaliz-
ability. Two studies of HIV-negative women found inflammatory
markers increased from the first to the third trimester, with levels
in one study returning to the first-trimester baseline by six months
postpartum [24]. The hypothesis that inflammation would be
further increased in the peri- and postpartum periods for HIV-
positive women is supported indirectly by some reports that CD4
T cell counts declined during pregnancy for women on triple
antiretroviral therapy [25] and HIV RNA increases from delivery
through the first 80 weeks postpartum for women not on therapy
or on mono- or combination therapy [26]. Viral load has been
linked to increased inflammation [27,28]. Direct evidence exists in
one study that found higher concentrations of b2-microglubulin
(but not TNF-a) in the third trimester of pregnancy and first weeks
postpartum among HIV-infected women compared with HIV-
uninfected controls [28], and the difference was identified up to six
months postpartum, in a separate study [29]. These studies suggest
that HIV-infected women experience changes in inflammatory
marker concentrations during pregnancy beyond those seen in
HIV-negative women with uncomplicated pregnancies, and these
changes persist for months beyond delivery. We found a decline in
hsCRP and D-dimer between the third trimester and six months
postpartum, but an increase in IFN-c. Given our finding that IFN-
c concentration was also associated with adverse clinical outcomes,
these data would suggest a mechanism for this relationship.
In contrast to other study results [13,15,18], we did not find a
significant association between hsCRP and subsequent adverse
clinical events. One possible explanation is that other studies have
examined populations that were exclusively or largely comprised
of men, and these populations were also significantly older and
individuals had more non-AIDS co-morbidities than Mashi
participants. The Mashi study overall recorded few cardiovascular
events as expected in this population of young women, and no
cardiovascular events in this study population. More data exist for
the association of standard, non high-sensitivity CRP and adverse
outcomes in studies of populations similar to Mashi, and CRP is
known to be associated with underlying infectious and inflamma-
tory conditions [13,30]. However, the predictive role of hsCRP is
unclear. To minimize confounding from concurrent infections in
our study, we excluded women with illness prior to or within two
months after the time of hsCRP testing. While we may have
unintentionally biased our selection toward a healthier population,
it likely gives a cleaner analysis of the association of hsCRP
elevation and subsequent adverse clinical events.
Prior studies have suggested that higher IL-10 and TNF-a
concentrations were associated with HIV-1 disease progression in
adult HIV-infection, as well as lower IFN-c with lower viral load
set point [31,32]. We found similar trends between these cytokines
and subsequent morbidity and mortality, independent of CD4 T
cell count and viral load.
There are several limitations to this study. As samples were only
collected and analyzed in the third trimester and at six months
postpartum, we do not know the pre-pregnancy baseline or how
marker concentrations changed during the first two trimesters of
pregnancy or at the time of delivery. It is possible that an analysis
of pre-pregnancy concentrations would yield different results.
Antiretroviral treatment was also not assigned as part of the study,
but given according to government guidelines. Our attempts to
control for this in the analysis may leave residual confounding.
Additionally, we looked at serum concentrations of six inflamma-
Figure 3. Changes in inflammatory marker concentrations between the third trimester and six months postpartum. The effect of time
between enrolment (antepartum) and six months postpartum on inflammatory marker levels – either as absolute concentrations or percentage of
women with detectable marker expression – was tested using generalized estimating equations (GEEs). Time and time*group interaction terms are
reported, adjusted for CD4 and viral load at enrolment, and whether HAART was initiated between sampling times.
doi:10.1371/journal.pone.0089928.g003
Table 3. Case-Control Study for Association of Inflammatory Marker Concentration and Major Adverse Clinical Events.
Mean (IQR) Inflammatory Marker Concentration Proportional Hazard Ratio for Major Adverse Clinical Eventa
n Case n Control p valueb Univariate 95% CI p valueb Multivariatec 95% CI p valueb
Viral load (log10
RNA copies/ml)
66 4.50
(3.4, 5.0)
129 4.18 (3.4, 4.8) .25 - - - - - -
CD4 count
(cells/ml)
59 343 (265,
502)
123 406 (330, 612) .05 - - - - - -
hsCRP 64 2.16 (0.79,
5.6)
122 1.99 (0.80, 4.6) .46 1.13 0.89–1.40 0.31 1.04 0.79–1.40 .76
IL-6 (pg/mL) 68 0.49 (0.12,
0.93)
132 0.76 (0.28, 1.3) .03 0.91 0.81–1.00 0.11 0.93 0.79–1.10 .32
D-dimer (pg/mL) 62 0.49 (0.30,
1.03)
116 0.44 (0.30, 0.61) .07 2.07 1.20–3.50 0.007 1.82 0.94–3.50 .07
TNFa (%) 66 80 (69, 89) 129 51 (42, 60) ,.001 3.60 1.80–7.10 ,0.001 4.16 1.70–9.90 .001
IFN-g (%) 68 34 (23, 46) 132 55 (46, 63) .005 0.45 0.25–0.82 0.009 0.37 0.17–0.82 .01
IL-10 (%) 62 48 (35, 61) 122 27 (19, 36) .004 2.09 1.10–3.80 0.02 2.26 1.00–4.90 .04
aThe model fit was a proportional hazards Cox model with appropriate weighting for the case-cohort design.
bP-values obtained from Wilcoxon signed rank (continuous) or Chi-Square (dichotomous) test.
cAdjusted for maternal age, calendar time of delivery, feeding strategy, HIV RNA load and CD4 count at 6 months post-partum.
doi:10.1371/journal.pone.0089928.t003
Immune Activation Markers in Peripartum Women
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e89928
tory marker proteins. An analysis of mRNA expression as cellular
markers of immune activation [33], or different soluble markers
such as markers of monocyte activation may have more accurately
reflected chronic inflammation and immune activation in this
population [34]. The markers we chose reflected previously
published studies and allowed us to compare our results to those
findings.
In summary, our data provide support for the need for further
investigation of the role of inflammation in clinical outcomes
among HIV-infected women peripartum (including the role of T
cell activation and monocyte activation), and of strategies to
reduce inflammation in the postpartum period. The randomized
study, Promoting Maternal-Infant Survival Everywhere (PROM-
ISE), is currently enrolling participants and aims to answer the
question of whether there is a benefit to women with CD4 cell
counts above current thresholds for treatment in continuing ART
initiated for PMTCT [35]. If pregnancy-related immune modu-
lation leads to an extended increase in inflammation postpartum
(with associated adverse clinical outcomes), this would add
evidence to support women remaining on ART after pregnancy,
regardless of CD4 count, for their own health [36,37].
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